This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Medifast Announces Partnership With The V Foundation For Cancer Research













OWINGS MILLS, Md., Feb. 11, 2014 /PRNewswire/ -- Medifast, Inc. (NYSE: MED), a leading United States manufacturer and provider of clinically proven, portion-controlled weight-loss products and programs announced today its partnership with The V Foundation for Cancer Research, one of the nation's leading cancer research funding organizations. As part of this multi-faceted partnership with The V Foundation, Medifast will fund research grants that explore the link between obesity and cancer and the impact of healthy living on preventing cancer-related diseases.

The partnership will kick off with the Medifast Slam Dunk Contest. Medifast will match clients' contributions to The V Foundation, which can be made at MedifastNow.com and at corporate Medifast Weight Control Centers from February 10 to March 10, 2014.  Additional events will be announced throughout the year with support from each of Medifast's distribution channels.

"Partnering with an outstanding organization like The V Foundation for Cancer Research is an extremely proud moment for Medifast, and we are humbled by the opportunity to help make a difference in a way that is very personal to us," said Mike MacDonald, Chairman and Chief Executive Officer of Medifast. "Our corporate contributions, event partnerships, and client contributions throughout the year combined with our matched funds will help The V Foundation continue their essential and urgent work in finding cures for cancer and builds upon our mission to support healthy living."

"We cannot express how grateful we are that Medifast is making The V Foundation for Cancer Research a priority," said Susan Braun, CEO of The V Foundation for Cancer Research. "This important partnership with Medifast provides critical support as we work to put an end to cancer. This is a natural fit for our organization, and we are excited to do great work together."

The first in a series of events, the Slam Dunk Contest commences on February 10 and runs through March 10, 2014.  No purchase, payment, or donation of any kind is necessary to enter or win the contest.  Additional terms and conditions apply. Please see MedifastNow.com for Official Contest Rules. Contestants may voluntarily donate to The V Foundation for Cancer Research at the time of entry into the contest. The Grand Prize package includes two (2) round-trip air transportation tickets, five (5) nights lodging, two (2) tickets to the Men's NCAA Semi-Finals and Championship college basketball games, and two (2) tickets to the Slam Dunk Concert with Darius Rucker at Gilley's in Dallas, TX.  The Total package is valued at approximately $5000.   

All received donations directly benefit The V Foundation for Cancer Research, which has funded more than $115 million in cancer research grants nationwide, with 100 percent of cash donations funding cancer research.

MED-G

About Medifast:

Medifast (NYSE: MED) is the leading easy-to-use, clinically proven, portion-controlled weight-loss program. The company sells its products and programs via four unique distribution channels: 1) the Web and national call centers, 2) the Take Shape For Life personal coaching division, 3) Medifast Weight Control Centers, and 4) a national network of physicians. Medifast was founded in 1980 and is located in Owings Mills, Maryland. For more information, log onto  www.MedifastNow.com.



1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,979.13 +59.54 0.35%
S&P 500 1,986.51 +4.91 0.25%
NASDAQ 4,526.4820 -1.0320 -0.02%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs